News Search Results
Dec 02, 2025, 09:00 ET TQ Therapeutics GmbH Enters into Technology Access Agreement with Kytopen
Kytopen continues expanding its partnership footprint in Europe through a new agreement with TQ Therapeutics GmbH, a Martinsried, Germany-based biotechnology company advancing next-generation cellular therapies.TQ Therapeutics, dedicated to advancing the field of cellular
More news about: Kytopen
Dec 02, 2025, 09:00 ET Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
cancer.In a recent pioneering study, researchers at Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, harnessed its AI-driven generative chemistry platform, Chemistry42, to design a novel, first-in-class PROTAC targeting PKMYT1, D16-M1P2,
More news about: Insilico Medicine
Dec 02, 2025, 09:00 ET Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer
MONTREAL, Dec. 2, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic
More news about: Thryv Therapeutics Inc.
Dec 02, 2025, 08:45 ET MetaVia Inc. Announces 1-for-11 Reverse Stock Split
Dec. 2, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia" or the "Company"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a 1-for-11 reverse stock split of its common stock, par value $0.001
More news about: MetaVia Inc.
Dec 02, 2025, 08:40 ET Truist Securities strengthens Equity Research coverage in high-growth sectors
/PRNewswire/ -- Truist Securities announced today several key hires to further strengthen its Equity Research coverage across the high-growth areas of Biotechnology, Energy, Financials, Technology, and Utilities. The addition of nine seasoned professionals reinforces Truist's commitment to building top-tier
More news about: Truist Financial Corporation
Dec 02, 2025, 08:00 ET Syantra Inc. to Showcase Breakthrough Research on Immune Reprogramming in Breast Cancer at SABCS 2025
team of innovators in biomedical engineering and medicine and supported by world-leading clinicians, Syantra Inc. is a privately held, precision biotechnology company pioneering a platform to change the way cancer is detected and managed. For more information, visit
More news about: Syantra Inc.
Dec 02, 2025, 07:00 ET Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting
BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will
More news about: Solu Therapeutics
Dec 02, 2025, 07:00 ET Origin Agritech's Pioneering Hi3 Gene Editing Technology Awarded as Top 10 Major Progress in Chinese Agricultural Science for 2025, as Company Advances Commercialization
Science for 2025 by the Chinese Academy of Agricultural Sciences. This prestigious recognition underscores Origin's leadership in agricultural biotechnology and highlights the transformative potential of its research to drive commercial advances in crop yields and sustainability. The selection
More news about: Origin Agritech Limited
Dec 02, 2025, 07:00 ET Nanoscope Therapeutics' MCO-010 Optogenetic Therapy Featured at FLORetina-ICOOR 2025 Congress
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
biologics, is fueling this robust market expansion. Top-tier decision-makers, including CEOs, Managers, and Directors across the pharmaceutical, biotechnology, and healthcare provider ecosystem, will find these market dynamics crucial for strategic planning, capital allocation, and maximizing shareholder
More news about: DataM Intelligence 4 Market Research LLP
Dec 02, 2025, 03:46 ET WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority
with Qatar's strategic vision for biopharmaceutical advancement, this collaboration aims to drive innovation, accelerate the growth of Qatar's biotechnology sector, while jointly propel the development of a robust Middle Eastern biopharmaceutical ecosystem.Dr. Chris Chen, CEO of WuXi Biologics,
More news about: WuXi Biologics
Dec 02, 2025, 02:00 ET ZAGENO Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Life Sciences E-commerce Leadership
environment. The company's continued investment in data-driven procurement intelligence and automation has enabled it to scale effectively across global biotechnology and pharmaceutical markets.Innovation remains central to ZAGENO's operating model. Its AI-powered, end-to-end procurement platform consolidates
More news about: Frost & Sullivan
Dec 02, 2025, 02:00 ET ZAGENO Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Life Sciences E-commerce Leadership
environment. The company's continued investment in data-driven procurement intelligence and automation has enabled it to scale effectively across global biotechnology and pharmaceutical markets.Innovation remains central to ZAGENO's operating model. Its AI-powered, end-to-end procurement platform consolidates
More news about: Frost & Sullivan
Dec 01, 2025, 17:54 ET Life Sciences Innovators Convene at BioFlorida's 28th Annual Innovation Conference
sciences community during the annual BioFlorida Awards Celebration. BioFlorida recognized outstanding achievements in eight categories, honoring GBI Biotechnology (Manufacturer), DermaSensor (Sales & Distribution), Anthony Japour of iTOLERANCE (Research & Developer), Nemours Children's Health (Hospital),
More news about: BioFlorida
Dec 01, 2025, 16:19 ET AVTR Class Action Reminder: Avantor, Inc. Investors Can Lead the Securities Class Action Lawsuit - Contact Robbins LLP for Information
Dec. 1, 2025 /PRNewswire/ -- Company: Avantor, Inc. (NYSE: AVTR) provides scientific products and services for customers in biotechnology, pharmaceuticals, healthcare, education, government, and other industries.
More news about: Robbins LLP
Dec 01, 2025, 14:28 ET Business transacted at the extraordinary general meeting of Aquaporin A/S
-- Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today held an extraordinary general meeting, at which the general meeting: Approved the proposal to amend the Articles
More news about: Aquaporin A/S
Dec 01, 2025, 14:15 ET Business transacted at the extraordinary general meeting of Aquaporin A/S
-- Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today held an extraordinary general meeting, at which the general meeting: Approved the proposal to amend the Articles
More news about: Aquaporin A/S
Dec 01, 2025, 08:00 ET Planet Green Holdings Corp. Unveiled New "Shengshengchuan Black Gold" Black Tea Series
/PRNewswire/ -- Planet Green Holdings Corp. ("Planet Green", the "Company") (NYSE American: PLAG) announced that its subsidiary Hubei Shengsili Biotechnology Co., Ltd. ("Shengsili") hosted a product launch event to debut its new Shengshengchuan Black Gold Series, an innovative line of black tea products
More news about: Planet Green Holdings Corp.
Dec 01, 2025, 08:00 ET Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
CARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Dec 01, 2025, 07:00 ET Q32 Bio Sells Complement Inhibitor ADX-097
WALTHAM, Mass., Dec. 1, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Dec 01, 2025, 06:00 ET Morphocell Technologies Completes US$50 Million Series A Financing
LAVAL, QC, Dec. 1, 2025 /PRNewswire/ - Morphocell Technologies Inc., a biotechnology company pioneering next-generation tissue therapeutics for organ replacement, today announced the completion of its US$50 million Series A financing
More news about: Morphocell Technologies
Dec 01, 2025, 06:00 ET Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study
SAN DIEGO, Dec. 1, 2025 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and
More news about: Protego Biopharma
Nov 30, 2025, 05:15 ET Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
https://voovmeeting.com/dm/10ve6whW8Rbl.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Nov 28, 2025, 17:50 ET MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman
FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly
More news about: Hagens Berman Sobol Shapiro LLP